Sponsors (3)
The bill preserves access and regulatory certainty for homeopathic manufacturers and users while substantially limiting FDA oversight and legal accountability, trading stronger consumer protections and enforcement for easier market access and lower compliance burdens for industry.
Consumers who use homeopathic products (including people with chronic conditions) will retain legal recognition and continued availability of homeopathic products through a distinct regulatory pathway, preserving consumer access.
Small manufacturers and sellers of homeopathic products gain regulatory certainty and lower compliance costs because premarket approval is not required and labeling/testing pathways are clarified, reducing time and cost to bring products to market.
FDA and HHS are given clearer statutory language and explicit authorities (including ability to apply recognized standards and establish an advisory committee and GMPs) to oversee homeopathic ingredients and manufacturing, which could streamline decisionmaking and standard-setting.
Patients, consumers, and healthcare systems face increased safety risks because the bill creates a lower/special regulatory pathway, exempts many homeopathic products from standard FDA drug requirements and identity/strength testing, and voids prior FDA guidance—increasing the chance that ineffective, mislabeled, or contaminated products reach the market.
FDA's authority to require premarket review, apply standard drug regulatory controls, and take enforcement action is substantially limited (including industry-favored timelines and automatic approvals if deadlines are missed), reducing regulators' ability to protect the public.
Taxpayers and consumers could bear increased economic costs from adverse events, recalls, or additional health care spending if weaker oversight leads to harms that require public intervention or treatment.
Based on analysis of 12 sections of legislative text.
Introduced January 14, 2026 by Pete Sessions · Last progress January 14, 2026
Creates a distinct federal regulatory pathway for homeopathic drug products that mostly exempts them from the standard drug approval and enforcement rules in the Food, Drug, and Cosmetic Act. The bill defines “homeopathic drug product” and “homeopathic ingredient,” sets labeling and manufacturing requirements tied to homeopathic pharmacopoeias or accredited consensus standards, prohibits routine FDA premarket approval for these products, establishes a Homeopathic Drug Product Advisory Committee, and voids a recent FDA guidance on homeopathic drugs.